Navigation Links
Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
Date:9/14/2009

ABBOTT PARK, Ill., Sept. 14 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials. The company plans a fourth-quarter launch for XIENCE V in China, which is the second-largest drug eluting stent market in the Asia-Pacific region after Japan. With approval in China, XIENCE V is now available in every Asia-Pacific market except Japan, where approval is anticipated at the end of this year.

"Since it first became commercially available in 2006, XIENCE V has become the market-leading drug eluting stent around the world due to its excellent outcomes and outstanding deliverability," said Robert Hance, senior vice president, vascular, Abbott. "As the incidence of heart disease and the number of annual stent procedures continue to increase in China, it is critical for physicians and patients to have access to one of the most advanced drug eluting stent technologies. We look forward to making XIENCE V available in China."

According to the China Chronic Heart Disease 2006 Annual Report, nearly 50 percent of all deaths annually in China are due to CAD, and the prevalence of coronary artery disease has steadily increased each year. Approximately 150,000 patients annually undergo a stent procedure for the treatment of CAD, and the number of procedures is growing by more than 20 percent each year in China.

"Heart disease is a
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
2. Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
3. Abbott HIV Test Demonstrates Earlier Disease Detection
4. Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
5. Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
6. Abbott Named One of the Top 10 Companies for Scientists
7. HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
8. Abbott to Present at Barclays Global Healthcare Conference
9. Abbott Employee Giving Sets New Records for Employee Participation and Total Donations
10. Abbott Announces 11 Percent Increase in Quarterly Dividend
11. Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... KONG , Oct. 22, 2014  aTyr Pharma ... that rare disease expert John C. McKew , ... McKew brings more than two decades of expertise in ... Institutes of Health, Wyeth Research and Genetics Institute, Inc. ... aTyr,s efforts to expand and translate its novel Physiocrine ...
(Date:10/20/2014)... MENLO PARK, Calif. , Oct. 20, 2014 ... announced today that the Company has signed a ... Institute of Regenerative Medicine (CIRM), effective October 1, ... of Clinical Development payments and the release of ... $14.3 million CIRM grant award for clinical development ...
(Date:10/20/2014)... PureTech , a science and ... problems, announced today the closing of a $55 ... Invesco Perpetual, a $120 Billion group of funds. ... existing pipeline forward and to advance new healthcare ... creativity to really go for the big ideas ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... , , , , , ... , , , , General ... set a, suitable plating protocol for optimal cell density from the beginning to, ... , Dividing versus Non-dividing Cells , Dividing cells ...
... , , , , , ... rapid and highly accurate identification of SNP loci. Our SeeSNP service ... fueled by our capacity , to sequence over 20 million ... facility apart include: , , ...
... , , , CleanSEQ is a SPRI-based dye-terminator ... centrifugation , or filtration steps. CleanSEQ produces superior quality sequencing ... dye-terminator removal , method in many of the top genomic ... HIGH QUALITY SEQUENCING RESULTS , , ...
Cached Biology Technology:General Considerations for Successful Transfection Experiments 2SEESNP DISCOVERY 2
(Date:10/15/2014)... Geneticist Fred Alt will be awarded the 44th Rosenstiel ... University for his pioneering research exploring the mechanisms of ... and cancer cells. Alt is the second alumnus to ... the Nobel Prize in 2003. , Alt is the ... Genetics at Harvard Medical School and an investigator at ...
(Date:10/14/2014)... years since T. rex took its last ... is breathing life back into dinosaurs using high-powered computer ... has important implications for how dinosaurs used their noses ... of smell and cool their brains. , "Dinosaurs ... Jason Bourke, lead author of the new study published ...
(Date:10/14/2014)... Montreal, October 14, 2014 – High doses of fish oil ... fibrillation, a common type of irregular heartbeat in which the ... The results of the AFFORD trial led by the Montreal ... American College of Cardiology on October 7th. , For ... antiarrhythmic therapy were randomly assigned to 4 grams of fish ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... three-dimensional plasmon rulers, capable of measuring nanometer-scale spatial ... researchers with the U.S. Department of Energy (DOE),s ... with researchers at the University of Stuttgart, Germany. ... unprecedented details on such critical dynamic events in ...
... awarded the University of Colorado Boulder a six-year, ... long-term ecological changes in Colorado,s high mountains, both ... Awarded to CU-Boulder,s Institute of Arctic and Alpine ... students, including undergraduates, to continue key environmental studies ...
... upon previous efforts producing a high-quality de ... E. coli O104:H4 outbreak ... their collaborators at the University Medical Centre ... map of the genome and plasmids without ...
Cached Biology News:Taking the 3-D measure of macromolecules: 2Taking the 3-D measure of macromolecules: 3NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 2NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 3NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research 4The complete map of the Germany E. coli O104 genome released 2
supplied with 10x reaction buffer...
... PBL's bioassays for interferons are cytopathic effect ... assays. Sample types include; tissue culture supernatents; ... In these assays, one unit is defined as ... reduce the cytopathic effect of viral infection by ...
... BioPrime Plus Array CGH Genomic Labeling Systems ... reproducible labeling of genomic DNA samples for ... both indirect and direct labeling formats, the ... provide a flexible solution to your genomic ...
... interferons are cytopathic effect inhibition assays, also known ... include; tissue culture supernatents; serum from PK studies ... unit is defined as the quantity of interferon ... of viral infection by 50%. All ...
Biology Products: